Showing 7701-7710 of 9133 results for "".
- Rezpegaldesleukin Shows Promise in Alopecia Areata in Phase 2b Trialhttps://practicaldermatology.com/news/rezpegaldesleukin-shows-promise-in-alopecia-areata-in-phase-2b-trial/2486426/Rezpegaldesleukin, an IL-2 pathway agonist designed to expand regulatory T cells (Tregs), demonstrated clinical efficacy and a favorable safety profile in patients with severe-to-very-severe alopecia areata (AA), according to Phase 2b REZOLVE-AA data presented by David Rosmarin, MD, at the Americ
- Zumilokibart Shows Rapid Symptom Relief in Atopic Dermatitishttps://practicaldermatology.com/news/zumilokibart-shows-rapid-symptom-relief-in-atopic-dermatitis/2486425/Zumilokibart (APG777), a half-life–extended anti–IL-13 monoclonal antibody, demonstrated rapid and sustained improvements in symptoms and quality of life in patients with moderate-to-severe atopic dermatitis (AD), according to Phase 2 APEX Part A results presented by Emma Guttman-Yassky, MD, PhD,
- AAD Updates Systemic Therapy Guidelines for Adult ADhttps://practicaldermatology.com/news/aad-updates-systemic-therapy-guidelines-for-adult-atopic-dermatitis/2486418/The American Academy of Dermatology (AAD) has issued an interim update to its clinical practice guidelines for systemic treatment of moderate to severe atopic dermatitis (AD) in adults, reflecting the rapid expansion of evidence supporting targeted therapies. The u
- Abrocitinib Shows Efficacy in Chronic Hand Eczema in Phase II Trialhttps://practicaldermatology.com/news/abrocitinib-shows-efficacy-in-chronic-hand-eczema-in-phase-ii-trial/2486424/Abrocitinib, an oral Janus kinase 1 (JAK1) inhibitor approved for atopic dermatitis, demonstrated significant efficacy in patients with chronic hand eczema (CHE) of diverse etiologies in a Phase II randomized trial presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting.
- Oral STAT6 Degrader KT-621 Shows Early Promise in Atopic Dermatitishttps://practicaldermatology.com/news/oral-stat6-degrader-kt-621-shows-early-promise-in-atopic-dermatitis/2486423/A first-in-class oral STAT6 degrader, KT-621, demonstrated early clinical activity, robust biomarker suppression, and a favorable safety profile in adults with moderate-to-severe atopic dermatitis (AD), according to Phase 1b data presented by Mahta Mortezavi, MD, at the American Academy of Dermat
- MG-K10 Shows Sustained Efficacy in Atopic Dermatitis Through 52 Weekshttps://practicaldermatology.com/news/mg-k10-shows-sustained-efficacy-in-atopic-dermatitis-through-52-weeks/2486421/A long-acting anti–IL-4 receptor alpha monoclonal antibody, MG-K10, demonstrated sustained efficacy and a favorable safety profile through 52 wee
- Povorcitinib Shows Durable Efficacy in HS in Phase 3 STOP-HS Trialshttps://practicaldermatology.com/news/povorcitinib-shows-durable-efficacy-in-hs-in-phase-3-stop-hs-trials/2486420/Late-breaking results from the Phase 3 STOP-HS1 and STOP-HS2 trials presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting showed that povorcitinib, an oral JAK1-selective inhibitor, achieved sustained efficacy and a manageable safety profile through 54 weeks in patients with
- Litifilimab Advances CLE Treatment With Positive Phase 2 Datahttps://practicaldermatology.com/news/litifilimab-advances-cle-treatment-with-positive-phase-2-data/2486419/Late-breaking data from the Phase 2 AMETHYST Part A trial presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting show that litifilimab, a monoclonal antibody targeting blood dendritic cell antigen 2 (BDCA2), improved disease activity in patients with cutaneous lupus erythemato
- ICONIC-LEAD: Durable Psoriasis Clearance Through 52 Weeks with Icotrokinrahttps://practicaldermatology.com/news/new-icotrokinra-data-shows-durable-psoriasis-clearance-through-52-weeks/2486414/The US Food and Drug Administration (FDA) recently granted approval for the oral interleukin (IL)-23 receptor antagonist icotrokinra (ICOTYDE™, Johnson & Johnson) for patients aged 12 years and older with moderate-to-severe plaque psoriasis who are candidates f
- ILDS, WHO Launch Global Dermatology Training Hub to Address Care Gapshttps://practicaldermatology.com/news/ilds-who-launch-global-dermatology-training-hub-to-address-care-gaps/2486380/The International League of Dermatological Societies (ILDS), in collaboration with the World Health Organization (WHO), has launched the ILDS Dermatology Training Hub, a free online platform aimed at expanding access to dermatology education worldwide. The initiati